To my knowledge it has only been compared to exantide BID, not exanitide LAR. The quick look I did only said it did better than BID, but no numbers or details were given.
Again, not unexpected at all. The future is 1x a week, i.e, exanitide LAR, so that is where the real comparisons will be made. Byetta bid is a good drug, but it is being improved upon.
So the answer is there are no such comparisons that I know of, and I have not seen any numbers to support the conclusions given by Roche for Taspoglutide. I would assume if the numbers were ground breaking the top line numbers at least would have been provided. Maybe they were in a more detailed press release, but I don't have the time to look it up at present if that is the case.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.